ArticleScientific reports2025
Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Assessment of Muscle Function Decline and Cachexia-Related Biomarkers in Hospitalized Oncology Patients: Study Protocol.Biomedicines · 2026Article
- Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2BMC cancer · 2026Article
- Adaptation of Enhanced Recovery After Surgery Protocol for Elective Gastrointestinal and Hepatopancreaticobiliary Surgeries for Tertiary Hospitals in Ethiopia: A Modified Delphi Study.World journal of surgery · 2026Article
- Article
- Article
- The impact of β-blockers on outcomes of immune checkpoint inhibitors therapy in advanced lung cancer: a multicenter real-world study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Eastern Cooperative Oncology Group performance status (ECOG-PS) is a widely used functional status measure in oncology, yet its prognostic value in upper tract urothelial carcinoma remains unclear. In this multicenter study of 2473 patients undergoing radical nephroureterectomy, ECOG-PS ≥ 2 was independently associated with worse overall survival (hazard ratio [HR] 2.53, p < 0.001), cancer-specific survival (HR 2.02, p < 0.001), and disease-free survival (HR 1.50, p = 0.003) than those with ECOG-PS 0-1. They also had a higher risk of major perioperative complications (odds ratio 2.46, p < 0.001). These findings support ECOG-PS as a valuable preoperative risk stratification tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.